C04180: Inhibitors of N-ethylmaleimide Sensitive Factor
Value Proposition:
This invention is a novel treatment for thrombotic disorders, such as myocardial infarction, stroke, deep venous thrombosis, pulmonary embolus, hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, sepsis, and microangiopathic hemolytic anemia. This invention may also be a novel treatment for disorders of exocytosis, including stroke and autoimmune diseases.
Technical Details:
JHU researchers have discovered that a previously described protein N-ethylmaleimide Sensitive Factor (NSF) regulates thrombosis. Inhibition of NSF, by certain cell permeable peptides, has been discovered as a novel method of anticoagulation. It has also discovered that these cell permeable NSF peptides inhibitors inhibit exocytosis.
Looking for Partners:
To develop and commercialize the technology as a novel treatment for thrombotic disorders and exocytosis disorders
Stage of Development:
Pre-Clinical
Data Availability:
Under CDA / NDA
Publications/Associated Cases:
Not available at this time
